HUE053114T2 - Fenfluramin kompozíciók és eljárások azok elõállítására - Google Patents

Fenfluramin kompozíciók és eljárások azok elõállítására

Info

Publication number
HUE053114T2
HUE053114T2 HUE16879990A HUE16879990A HUE053114T2 HU E053114 T2 HUE053114 T2 HU E053114T2 HU E16879990 A HUE16879990 A HU E16879990A HU E16879990 A HUE16879990 A HU E16879990A HU E053114 T2 HUE053114 T2 HU E053114T2
Authority
HU
Hungary
Prior art keywords
preparing
methods
same
fenfluramine compositions
fenfluramine
Prior art date
Application number
HUE16879990A
Other languages
English (en)
Inventor
Derek Londesbrough
Marc W Andersen
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59065032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE053114(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of HUE053114T2 publication Critical patent/HUE053114T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/24Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds
    • C07C209/28Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with other reducing agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82Purification; Separation; Stabilisation; Use of additives
    • C07C209/84Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78Separation; Purification; Stabilisation; Use of additives
    • C07C45/80Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/233Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/08Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/43Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HUE16879990A 2015-12-22 2016-12-20 Fenfluramin kompozíciók és eljárások azok elõállítására HUE053114T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562271172P 2015-12-22 2015-12-22

Publications (1)

Publication Number Publication Date
HUE053114T2 true HUE053114T2 (hu) 2021-06-28

Family

ID=59065032

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16879990A HUE053114T2 (hu) 2015-12-22 2016-12-20 Fenfluramin kompozíciók és eljárások azok elõállítására

Country Status (24)

Country Link
US (4) US10351509B2 (hu)
EP (3) EP4293009A3 (hu)
JP (3) JP6893213B2 (hu)
KR (1) KR102688278B1 (hu)
CN (2) CN108883399B (hu)
AU (3) AU2016379346B2 (hu)
BR (1) BR112018011777A2 (hu)
CA (1) CA3007286A1 (hu)
DK (1) DK3393655T3 (hu)
ES (1) ES2861774T3 (hu)
HR (1) HRP20210267T1 (hu)
HU (1) HUE053114T2 (hu)
IL (3) IL286391B (hu)
LT (1) LT3393655T (hu)
MX (1) MX2021000482A (hu)
PL (1) PL3393655T3 (hu)
PT (1) PT3393655T (hu)
RS (1) RS61506B1 (hu)
RU (2) RU2020128323A (hu)
SA (1) SA518391868B1 (hu)
SG (2) SG11201804811WA (hu)
SI (1) SI3393655T1 (hu)
WO (1) WO2017112702A1 (hu)
ZA (1) ZA201803583B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP4293009A3 (en) 2015-12-22 2024-02-21 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US20180055789A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
WO2020112460A1 (en) * 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
EP4031114A1 (en) 2019-09-17 2022-07-27 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
WO2021117057A1 (en) * 2019-12-10 2021-06-17 Maithri Drugs Pvt Ltd Polymorph of n-ethyl-1-(3-(trifluoromethyl)phenyl)propan-2-amine hydrochloride and process for preparation thereof
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023037182A2 (en) * 2021-08-19 2023-03-16 Biophore India Pharmaceuticals Pvt Ltd AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- α -METHYL-3-(TRIFLUOROMETHYL)PHENETHYLAMINE HYDROCHLORIDE

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (hu) * 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) * 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
JPS54144347A (en) * 1978-05-02 1979-11-10 Nikken Kagaku Kk 3-(2-fluoro-4-biphenylyl)-2-butanone
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) * 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
KR870001541B1 (ko) * 1985-06-14 1987-09-02 미쯔이도야쯔 가가꾸 가부시기 가이샤 에폭시수지 경화용 아미노벤질아민 조성물
US4721823A (en) * 1986-09-19 1988-01-26 Pennzoil Products Company Lubricants comprising novel cyclopentanes, cyclopentadienes, cyclopentenes, and mixtures thereof and methods of manufacture
DE3717434C1 (de) * 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
KR890003368A (ko) * 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
US4857533A (en) 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) * 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
EP0712387B1 (en) 1993-08-06 1999-12-08 PHARMACIA & UPJOHN COMPANY 2-aminoindans as selective dopamine d3 ligands
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
JP3839049B2 (ja) 1994-06-03 2006-11-01 テムド トラスト メタ位置換のアリルアルキルアミン類ならびに治療および診断のためのその使用
IT1298349B1 (it) * 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) * 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
AU2001275095A1 (en) 2000-07-17 2002-01-30 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7585493B2 (en) * 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
JP2004530436A (ja) 2001-06-22 2004-10-07 ユニべルシテ・カトリック・ドゥ・ルベン 昆虫の産卵および内部捕食寄生生物の飼養のための人工培地としてのヒドロゲルビーズまたはカプセル
WO2003011306A1 (en) 2001-07-31 2003-02-13 Wyeth Sucralose formulations to mask unpleasant tastes
AUPR732601A0 (en) * 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
RU2317104C2 (ru) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
US7091245B2 (en) * 2002-09-05 2006-08-15 Novo Novdisk A/S Compounds, their preparation and use
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
KR20080072105A (ko) * 2004-08-26 2008-08-05 화이자 인코포레이티드 단백질 티로신 키나제 저해제 중간체의 제조를 위한거울상이성질선택적 생물학적 전환
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
CN100567252C (zh) * 2004-10-11 2009-12-09 俞锋 盐酸芬氟拉明原料药和片剂及其制备方法
JP2008536545A (ja) 2005-03-21 2008-09-11 ヘルス−スマート リミテッド 連続血圧モニタリングのためのシステム
EP1888030A1 (en) 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
WO2006133508A1 (en) 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
WO2007031846A2 (en) 2005-09-14 2007-03-22 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
US8109891B2 (en) 2005-09-19 2012-02-07 Biolert Ltd Device and method for detecting an epileptic event
EP3703058A1 (en) 2005-11-29 2020-09-02 Children's Hospital Medical Center A method of selecting a medication for a patient
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
BRPI0707518A2 (pt) 2006-02-06 2011-05-10 Novartis Ag combinaÇço de compostos orgÂnicos
EP2041065A2 (en) * 2006-06-08 2009-04-01 Medichem, S.A. Processes for preparing cinacalcet hydrochloride and polymorphic forms thereof
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
CA2660431C (en) 2006-08-31 2015-03-17 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators
JP2010518489A (ja) 2007-01-31 2010-05-27 クインタイルズ トランスナショナル コーポレイション サイトスタートアップのための方法とシステム
WO2008096271A2 (en) 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
EP2125799A1 (en) 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
CA2732131A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
EP2331210B1 (en) 2008-09-05 2014-07-09 Grünenthal GmbH Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
US8664442B2 (en) * 2008-09-09 2014-03-04 Chemtura Corporation Anti-oxidants
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
EP2349207B1 (en) 2008-10-09 2015-05-13 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Liquid pharmaceutical formulation containing paracetamol
EP2355818A4 (en) 2008-10-10 2012-04-11 Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res METHODS AND COMPOSITIONS FOR TREATING A CONDITION OF EPILEPTIC DISEASE AND EPILEPSY CRISES CAUSING EPILEPTIC DISEASE CONDITION
TWI503101B (zh) 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
WO2010104841A2 (en) 2009-03-09 2010-09-16 Celgene Corporation Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US20110212171A1 (en) 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011112606A1 (en) 2010-03-09 2011-09-15 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
AU2011255276B2 (en) 2010-05-21 2016-09-22 Research Triangle Institute Phenylmorpholines and analogues thereof
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
AU2011283008A1 (en) 2010-07-30 2013-01-24 Merck Sharp & Dohme Corp. Inhibition of CYP3A drug metabolism
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ht2c 작동제의 변형-방출 투여 형태
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
AU2011322147A1 (en) 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US8748418B2 (en) * 2011-03-18 2014-06-10 Hoffmann-La Roche Inc. 1,4-oxazepines as BACE1 and/or BACE2 inhibitors
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
CN104918923A (zh) 2012-11-15 2015-09-16 加林制药公司 新型口服生物可利用的呼吸控制调节化合物及其使用方法
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103342648A (zh) * 2013-07-22 2013-10-09 北京科莱博医药开发有限责任公司 瑞替加滨中间体的制备方法和瑞替加滨的制备方法
ES2813450T3 (es) 2013-08-19 2021-03-23 Univ California Compuestos y métodos para tratar un trastorno epiléptico
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20150141415A1 (en) 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
JP6466116B2 (ja) 2014-09-12 2019-02-06 株式会社東芝 運行制御システム
US10452815B2 (en) 2014-09-29 2019-10-22 Zogenix International Limited Control system for control of distribution of medication
US20160228454A1 (en) 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders
EA201992474A3 (ru) 2015-02-25 2020-05-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Агонисты 5ht для лечения нарушений
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的5−ht受容体アゴニストおよびアンタゴニスト
EP3310362B1 (en) 2015-06-17 2019-08-28 The Trustees of Columbia University in the City of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
JP6731427B2 (ja) 2015-06-30 2020-07-29 ネウラッド リミテッドNeurad Ltd. 新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
EP3324975B1 (en) 2015-07-22 2022-05-18 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
KR20180054584A (ko) 2015-08-24 2018-05-24 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP4293009A3 (en) * 2015-12-22 2024-02-21 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
WO2017122701A1 (ja) 2016-01-14 2017-07-20 旭硝子株式会社 フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
US20180055789A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
MX2019013279A (es) 2017-05-09 2020-01-15 Zogenix International Ltd Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190091174A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of reducing seizure type experienced by a dravet patient
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
WO2019204593A1 (en) 2018-04-18 2019-10-24 The Trustees Of Columbia University In The City Of New York Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020014075A1 (en) 2018-07-10 2020-01-16 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
US20200030260A1 (en) 2018-07-27 2020-01-30 Xenon Pharmaceuticals Inc. Method for treating epilepsy
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
WO2020112460A1 (en) 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
EP3930841A4 (en) 2019-02-25 2022-11-30 Zogenix International Limited FORMULATION TO IMPROVE SEIZURE CONTROL
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine

Also Published As

Publication number Publication date
US20190284124A1 (en) 2019-09-19
LT3393655T (lt) 2021-03-25
RU2018121633A3 (hu) 2020-03-20
AU2021201339B2 (en) 2021-10-21
EP3393655A1 (en) 2018-10-31
CA3007286A1 (en) 2017-06-29
AU2021201339A1 (en) 2021-03-18
JP7412320B2 (ja) 2024-01-12
US10947183B2 (en) 2021-03-16
US20210147335A1 (en) 2021-05-20
EP4293009A2 (en) 2023-12-20
RU2018121633A (ru) 2020-01-23
SG10202005916QA (en) 2020-07-29
RS61506B1 (sr) 2021-03-31
US20170174613A1 (en) 2017-06-22
AU2016379346A1 (en) 2018-07-05
PT3393655T (pt) 2021-02-23
CN108883399A (zh) 2018-11-23
BR112018011777A2 (pt) 2018-12-04
US20180148403A1 (en) 2018-05-31
RU2020128323A3 (hu) 2021-01-29
US11634377B2 (en) 2023-04-25
KR20180091924A (ko) 2018-08-16
IL281368B (en) 2021-10-31
JP2021054831A (ja) 2021-04-08
US10351510B2 (en) 2019-07-16
SG11201804811WA (en) 2018-07-30
WO2017112702A1 (en) 2017-06-29
EP3393655B1 (en) 2020-12-09
IL286391A (en) 2021-10-31
RU2020128323A (ru) 2020-10-06
KR102688278B1 (ko) 2024-07-26
AU2021202576B2 (en) 2022-03-03
PL3393655T3 (pl) 2021-09-20
MX2021000482A (es) 2022-03-29
JP2022133279A (ja) 2022-09-13
HRP20210267T1 (hr) 2021-05-14
EP3800177A1 (en) 2021-04-07
CN108883399B (zh) 2021-06-22
IL259703B (en) 2021-04-29
EP3393655A4 (en) 2019-07-24
DK3393655T3 (da) 2021-03-15
SI3393655T1 (sl) 2021-05-31
US10351509B2 (en) 2019-07-16
RU2731179C2 (ru) 2020-08-31
AU2016379346B2 (en) 2021-02-18
ES2861774T3 (es) 2021-10-06
JP6893213B2 (ja) 2021-06-23
JP7394919B2 (ja) 2023-12-08
IL281368A (en) 2021-04-29
IL259703A (en) 2018-07-31
ZA201803583B (en) 2019-03-27
CN113499330A (zh) 2021-10-15
SA518391868B1 (ar) 2021-09-08
IL286391B (en) 2022-08-01
EP4293009A3 (en) 2024-02-21
AU2021202576A1 (en) 2021-05-27
JP2019501173A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
IL286391A (en) Penfluramine preparations and methods for their preparation
HRP20192145T1 (hr) Pripravci nosača-antitijela i metode pripreme i uporabe istih
HK1256726A1 (zh) 載體結合劑組合物及其製備和使用方法
GB2546350B (en) Compositions and methods
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
GB201718876D0 (en) Antithrombin-heparin compositions and methods
GB201519128D0 (en) Solid forms and methods of preparing the same
EP3166892A4 (en) Scale-inhibition compositions and methods of making and using the same
EP3518910A4 (en) MIDODRIN COMPOSITIONS AND METHOD OF USE THEREOF
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
HK1250345A1 (zh) 包含15-氧代-epa或15-氧代-dgla的組合物及其製備和使用方法
GB201621294D0 (en) Compositions and uses and methods relating thereto
IL259583A (en) Collagen preparations 7 and methods of using them
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
GB201715820D0 (en) Compositions and methods
GB201512996D0 (en) Compositions and methods
GB201514413D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions
IL256261B (en) Hide1 compositions and methods
GB201522554D0 (en) Methods and compositions
GB201518167D0 (en) Methods and compositions
GB201514415D0 (en) Compositions and methods